Related Experiment Video
Updated: May 25, 2026
10:19
Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
[Antibody therapy for Alzheimer's disease]
Takeshi Tabira1, Shin-Ei Matsumoto, Haifeng Jin
1Department of Diagnosis, Prevention and Treatment of Dementia, Graduate School of Medicine, Juntendo University.
Rinsho Shinkeigaku = Clinical Neurology
|January 27, 2012
Summary
Researchers are developing antibodies to treat Alzheimer's disease by targeting amyloid-beta. A new TAPIR-like antibody shows promise, preferentially reacting with amyloid-beta oligomers, potentially offering a new therapeutic avenue.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Context:
- Alzheimer's disease (AD) is characterized by amyloid-beta (Abeta) plaques.
- Current AD therapeutics in clinical trials include monoclonal and polyclonal antibodies targeting Abeta.
- Abeta-induced autoimmune encephalitis is a potential side effect of these immunotherapies.
Purpose:
- To review current antibody-based therapies for Alzheimer's disease.
- To investigate the role of tissue amyloid plaque immuno-reactive (TAPIR) antibodies in AD progression.
- To introduce a novel TAPIR-like monoclonal antibody targeting Abeta oligomers.
Summary:
- Several antibodies (bapineuzumab, solanezumab, etc.) targeting different Abeta epitopes are in clinical trials for AD.
- The efficacy of these antibodies for Alzheimer's disease remains undetermined pending trial results.
- A newly developed TAPIR-like monoclonal antibody demonstrates preferential reactivity with Abeta oligomers, suggesting potential therapeutic benefits.
Impact:
- Highlights the ongoing development of immunotherapies for Alzheimer's disease.
- Suggests that targeting Abeta oligomers may be a promising strategy for AD treatment.
- Emphasizes the need for continued clinical trials to determine the effectiveness of various antibody-based approaches.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...